Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Tisagenlecleucel (Kymriah®)	TA554 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years TA567 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tivozanib	TA512 - Tivozanib for treating advanced renal cell carcinoma
Tocilizumab (Tyenne® Roactemra®)	TA247 - Rheumatoid arthritis - tocilizumab (rapid review TA198) TA238 - Tocilizumab for the treatment of systemic juvenile idiopathic arthritis TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis	Hospital use only
Tofacitinib (Xeljanz®)	TA480 - Tofacitinib for moderate to severe rheumatoid arthritis TA543 - Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs TA735 - Tofacitinib for treating juvenile idiopathic arthritis TA920 - Tofacitinib for treating active ankylosing spondylitis
Tofacitinib (Xeljanz®)	TA547 - Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan (Jinarc®)	TA358 - Tolvaptan for treating autosomal dominant polycystic kidney disease	Tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease
Topotecan capsules	TA184 - Topotecan for the treatment of relapsed small-cell lung cancer	For hospital use only
Trametinib	TA396 - Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trastuzumab deruxtecan (Enhertu®)	TA704 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies TA862 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
Trastuzumab emtansine	TA34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.